Announcement PDF ASX ANNOUNCEMENT 23 September 2026 R&D TAX INCENTIVE LOAN FACILITY HITIQ Limited (‘HITIQ’ or the ‘Company’) (ASX: HIQ) advises entered into a new R&D Tax incentive loan facility (RDTI Loan) with No Bull Health Pty Ltd (No Bull), a related party of the Company's largest shareholder, Harmil Angel Investments (Harmil). The RDTI Loan will initially be unsecured, with shareholder approval to be sought at the Company's upcoming AGM for a Specific Security Agreement to be entered into with No Bull such that the RDTI Loan is secured against forecast R&D expenditure, which is consistent for such a facility. The previous facility entered into will be repaid upon receipt of the FY26 Tax Incentive Refund with any shortfall rolled into this facility. The RDTI Loan is on an arms-length basis, with standard terms and conditions for a facility of this type, including: • Loan Amount: $1,500,000 • Maturity Date: Rolling facility, subject to annual review • Final Tax Claim Date: 30 June 2027 • Interest Rate: 12% per annum • Application Fee: $5,500.00 (Incl GST) An initial drawdown of $750,000 has been completed under the RDTI Loan. HITIQ’s Executive Chairman, Earl Eddings said, “This facility provides funding certainty and ongoing support for HITIQ’s global growth strategy across the consumer, elite sport and military markets. We remain focused on disciplined execution, expanding the commercial adoption of our technology and delivering value for shareholders." About PROTEQT™ PROTEQT™, co-developed with Shock Doctor, is HITIQ's concussion management and athlete safety solution that delivers real-time head impact data through an instrumented mouthguard and analytics platform. About HITIQ HITIQ Limited (ASX: HIQ) develops head impact measurement and concussion management technology for sport, clinical, research and defence applications worldwide. The Company’s PROTEQT instrumented smart mouthguard and analytics platform deliver head impact data to athletes, clubs, leagues and clinicians, and the same core sensor technology underpins PROTEQT D-MAX, developed for defence applications. Authorised for release by the Board of HITIQ Limited For further information, contact: investors@hitiq.com